BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34755663)

  • 1. [Vascular endothelial growth factor promotes cancer stemness of triple-negative breast cancer via MAPK/ERK pathway].
    Wang L; Zhao L; Zhang L; Jing X; Zhang Y; Shao S; Zhao X; Luo M
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Oct; 41(10):1484-1491. PubMed ID: 34755663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
    Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
    BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
    Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
    Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Schlafen12 Reduces the Aggressiveness of Triple Negative Breast Cancer through Post-Transcriptional Regulation of ZEB1 That Drives Stem Cell Differentiation.
    Al-Marsoummi S; Vomhof-DeKrey E; Basson MD
    Cell Physiol Biochem; 2019; 53(6):999-1014. PubMed ID: 31838790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metalloprotease-dependent activation of EGFR modulates CD44
    Wise R; Zolkiewska A
    Breast Cancer Res Treat; 2017 Nov; 166(2):421-433. PubMed ID: 28791489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis.
    Xu X; Zhang L; He X; Zhang P; Sun C; Xu X; Lu Y; Li F
    Biochem Biophys Res Commun; 2018 Jul; 502(1):160-165. PubMed ID: 29792857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIF-2α regulates CD44 to promote cancer stem cell activation in triple-negative breast cancer
    Bai J; Chen WB; Zhang XY; Kang XN; Jin LJ; Zhang H; Wang ZY
    World J Stem Cells; 2020 Jan; 12(1):87-99. PubMed ID: 32110277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tryptophan hydroxylase 1 and 5-HT
    Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
    Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STAT3-induced HLA-F-AS1 promotes cell proliferation and stemness characteristics in triple negative breast cancer cells by upregulating TRABD.
    Wu D; Jia H; Zhang Z; Li S
    Bioorg Chem; 2021 Apr; 109():104722. PubMed ID: 33618253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different mechanisms involved in the berberine-induced antiproliferation effects in triple-negative breast cancer cell lines.
    Lin YS; Chiu YC; Tsai YH; Tsai YF; Wang JY; Tseng LM; Chiu JH
    J Cell Biochem; 2019 Aug; 120(8):13531-13544. PubMed ID: 30957305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VEGF-A/Neuropilin 1 Pathway Confers Cancer Stemness via Activating Wnt/β-Catenin Axis in Breast Cancer Cells.
    Zhang L; Wang H; Li C; Zhao Y; Wu L; Du X; Han Z
    Cell Physiol Biochem; 2017; 44(3):1251-1262. PubMed ID: 29179185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carboxypeptidase A4 negatively correlates with p53 expression and regulates the stemness of breast cancer cells.
    Wang Y; Xie Y; Niu Y; Song P; Liu Y; Burnett J; Yang Z; Sun D; Ran Y; Li Y; Sun L
    Int J Med Sci; 2021; 18(8):1753-1759. PubMed ID: 33746592
    [No Abstract]   [Full Text] [Related]  

  • 13. Chinese medicine formula 'Baipuhuang Keli' inhibits triple-negative breast cancer by hindering DNA damage repair via MAPK/ERK pathway.
    Mi S; Liu X; Zhang L; Wang Y; Sun L; Yuan S; Cui M; Liu Y
    J Ethnopharmacol; 2023 Mar; 304():116077. PubMed ID: 36572327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Myc expression and transcription activity underlies intra-tumoral heterogeneity in triple-negative breast cancer.
    Gupta N; Jung K; Wu C; Alshareef A; Alqahtani H; Damaraju S; Mackey JR; Ghosh S; Sabri S; Abdulkarim BS; Bigras G; Lai R
    Oncotarget; 2017 Apr; 8(17):28101-28115. PubMed ID: 28427212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noninvasive
    Henry KE; Dilling TR; Abdel-Atti D; Edwards KJ; Evans MJ; Lewis JS
    J Nucl Med; 2018 Jan; 59(1):51-57. PubMed ID: 28848040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
    Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
    Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2.
    Zhao D; Pan C; Sun J; Gilbert C; Drews-Elger K; Azzam DJ; Picon-Ruiz M; Kim M; Ullmer W; El-Ashry D; Creighton CJ; Slingerland JM
    Oncogene; 2015 Jun; 34(24):3107-19. PubMed ID: 25151964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VEGF/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-κB and β-catenin.
    Luo M; Hou L; Li J; Shao S; Huang S; Meng D; Liu L; Feng L; Xia P; Qin T; Zhao X
    Cancer Lett; 2016 Apr; 373(1):1-11. PubMed ID: 26805761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol (SQ) inhibits cancer cell metastasis behavior of TNBC via suppressing EMT and VEGF.
    Zheng D; Wu Z; Han J; Guan Q; Li Z; Zuo D; Zhang W; Wu Y
    Chem Biol Interact; 2020 Sep; 329():109202. PubMed ID: 32717189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.